Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Trading 11-14 13:23:56 EST

0.5158

+0.0046

+0.90%

High0.5240	Low0.5001	Vol166.98K
Open0.5124	D1 Closing0.5112	Amplitude4.68%
Mkt Cap21.30M	Tradable Cap12.84M	Total Shares41.30M
T/O85.40K	T/O Rate0.67%	Tradable Shares24.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":0.5158,"timestamp":1731608623785,"preClose":0.5112,"halted":0,"volume":166979,"delay":0,"floatShares":24893477,"shares":41302599,"eps":-0.960027,"marketStatus":"Trading","change":0.0046,"latestTime":"11-14 13:23:56 EST","open":0.5124,"high":0.524,"low":0.5001,"amount":85399.238823,"amplitude":0.046753,"askPrice":0.5238,"askSize":100,"bidPrice":0.5158,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-0.960027,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1731618000000},"marketStatusCode":2,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":0.5112,"preHourTrading":{"tag":"盘前","latestPrice":0.5071,"preClose":0.5112,"latestTime":"08:00 EST","volume":900,"amount":456.39,"timestamp":1731589200608},"postHourTrading":{"tag":"盘后","latestPrice":0.522,"preClose":0.5112,"latestTime":"19:47 EST","volume":2531,"amount":1343.985,"timestamp":1731545241783},"volumeRatio":0.906291,"impliedVol":1.7522,"impliedVolPercentile":0.6831},"requestUrl":"/m/hq/s/SPRB/wiki","defaultTab":"wiki","newsList":[{"id":"2483544805","title":"Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2483544805","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483544805?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:57","pubTimestamp":1731589029,"startTime":"0","endTime":"0","summary":"NasdaqCM:SPRB Earnings and Revenue Growth November 14th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 42%. Earnings per share  exceeded analyst estimates by 17%.Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 6.0% from a week ago.It is worth noting though that we have found 3 warning signs for Spruce Biosciences (1 is a bit concerning!) that you need to take into consideration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-third-quarter-2024-125709163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRB"],"gpt_icon":0},{"id":"2483044600","title":"Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483044600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483044600?lang=en_us&edition=fundamental","pubTime":"2024-11-13 14:01","pubTimestamp":1731477672,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc. (SPRB) has disclosed a new risk, in the Share Price & Shareholder Rights category. Spruce Biosciences, Inc. faces a signif...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-faces-nasdaq-delisting-threat-can-a-reverse-stock-split-save-its-market-presence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-faces-nasdaq-delisting-threat-can-a-reverse-stock-split-save-its-market-presence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QID","BK4588","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","SPRB","NQmain","NDAQ","IE00B64PRP62.GBP","BK4112","PSQ","LU2210150020.SGD","TQQQ",".IXIC","LU2095319765.USD","MNQmain","IE00BGHQF748.EUR","SQQQ","BK4585","QLD"],"gpt_icon":0},{"id":"2482089254","title":"Spruce Biosciences Price Target Maintained With a $2.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2482089254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482089254?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:05","pubTimestamp":1731423900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2024 10:05 ET (15:05 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2482770747","title":"RBC Capital Sticks to Their Hold Rating for Spruce Biosciences (SPRB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482770747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482770747?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:38","pubTimestamp":1731411517,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Gregory Renza maintained a Hold rating on Spruce Biosciences (SPRB – Research Report) yesterday and set a price target of $2.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-hold-rating-for-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB"],"gpt_icon":0},{"id":"2482071716","title":"Spruce Biosciences Reports Q3 2024 Earnings and Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2482071716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482071716?lang=en_us&edition=fundamental","pubTime":"2024-11-12 11:59","pubTimestamp":1731383996,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc. ( ($SPRB) ) has released its Q3 earnings. Here is a breakdown of the information Spruce Biosciences, Inc. presented to its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-reports-q3-2024-earnings-and-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-reports-q3-2024-earnings-and-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB"],"gpt_icon":0},{"id":"2482360857","title":"Spruce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482360857","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482360857?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:31","pubTimestamp":1731339091,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc reports results for the quarter ended September 30 - Earnings SummarySpruce Biosciences Inc SPRB.OQ reported a quarterly adjusted loss of 21 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL8N3MI159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2482674731","title":"Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2482674731","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482674731?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:10","pubTimestamp":1731334204,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.  came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this company would post a loss of $0.33 per share when it actually produced a loss of $0.22, delivering a surprise of 33.33%.Spruce Biosciences , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.6 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 66.56%. This compares to year-ago revenues of $3.07 million. The company has topped consensus revenue estimates three times over the last four quarters.Spruce Biosciences shares have lost about 81.7% since the beginning of the year versus the S&P 500's gain of 25.7%.While Spruce Biosciences has underperformed the market so far this ye","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-inc-sprb-reports-141004832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRB"],"gpt_icon":0},{"id":"2482789709","title":"Spruce Biosciences Q3 EPS $(0.21) Beats $(0.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482789709","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482789709?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:18","pubTimestamp":1731331101,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is a 30 percent increase over losses of $(0.30) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41877431/spruce-biosciences-q3-eps-0-21-beats-0-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Spruce Biosciences Q3 EPS $(0.21) Beats $(0.24) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2482442789","title":"Spruce Biosciences reports Q3 EPS (21c), consensus (24c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482442789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482442789?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:11","pubTimestamp":1731330685,"startTime":"0","endTime":"0","summary":"Reports Q revenue $602K, consensus $1.49M. “We remain on track to report primary efficacy and safety data plus interim data from the open-label ext...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-reports-q3-eps-21c-consensus-24c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spruce-biosciences-reports-q3-eps-21c-consensus-24c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRB"],"gpt_icon":0},{"id":"2482878691","title":"Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2482878691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482878691?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA13NNK3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPRB","BK4139"],"gpt_icon":0},{"id":"2482786467","title":"Spruce Biosciences: Cash, Cash Equivalents Expected to Allow Co to Fund Operating Plan Through 2025 End","url":"https://stock-news.laohu8.com/highlight/detail?id=2482786467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482786467?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA13NNK3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SPRB"],"gpt_icon":0},{"id":"2482895047","title":"Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2482895047","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482895047?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia  Anticipated in December 2024. Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Anticipated in December 2024. CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH: CAHptain-205 is a Phase 2 open-label clinical trial, which utilizes a sequential nine cohort design, to evaluate the safety, efficacy, and pharmacokinetics of tildacerfont in adults and children between two and 17 years of age. Cohorts 1-3 evaluated weight-adjusted doses of tildacerfont between 50mg QD and 200mg QD in pediatric CAH patients between two and 17 years of age, and assessed changes in androgen levels over 12 weeks of treatment as well as the ability to reduce daily GC dose based on A4 normali","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rsQhwehUjU_j8qqoqA0CuQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/084a09e7aa29b73de188ce7e9dcd7516","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rsQhwehUjU_j8qqoqA0CuQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/084a09e7aa29b73de188ce7e9dcd7516"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-reports-third-quarter-130000514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","LU1880398554.USD","BK4175","LU0211328371.USD","LU0128525689.USD","LU0889566641.SGD","LU1267930813.SGD","LU0072461881.USD","BK4503","LU0052756011.USD","LU1267930490.SGD","BK4166","QD","SPRB","LU1267930227.SGD","BK4588","LU0792757196.USD","LU1571399168.USD","LU0211327993.USD","CAH","LU0006061336.USD","LU1880398471.USD","BK4585","LU0310799852.SGD","LU0162691827.USD","BK4139","LU0310800965.SGD","SG9999001440.SGD"],"gpt_icon":0},{"id":"2481483287","title":"Spruce Biosciences Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481483287","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481483287?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:53","pubTimestamp":1731081233,"startTime":"0","endTime":"0","summary":"Spruce Biosciences Inc  expected to post a loss of24cents a share - Earnings Preview Spruce Biosciences Inc SPRB.OQ SPRB.O is expected to show a fall in quarterly revenue when it reports  results on N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF28G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2479045435","title":"Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479045435","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479045435?lang=en_us&edition=fundamental","pubTime":"2024-10-29 04:01","pubTimestamp":1730145660,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., October 28, 2024----Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET.Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF1 receptor antagonist, for the treatment of congenital adrenal hyperplasia , ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JBlTjmchFVUbfCUN0Ey.Fw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/095b32d338fbae07d4a8775eb9adaaa5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JBlTjmchFVUbfCUN0Ey.Fw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/095b32d338fbae07d4a8775eb9adaaa5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-participate-guggenheim-securities-200100051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0162691827.USD","LU1880398471.USD","LU0792757196.USD","LU1267930227.SGD","SG9999001440.SGD","HCSG","LU0211328371.USD","LU0006061336.USD","BK4139","BK4137","CAH","LU1880398554.USD","BK4175","LU0211327993.USD","LU1571399168.USD","LU1267930490.SGD","BK4585","LU0128525689.USD","LU0310799852.SGD","SPRB","LU0052756011.USD","LU0310800965.SGD","BK4588","LU0889566641.SGD","LU1267930813.SGD","LU0072461881.USD"],"gpt_icon":0},{"id":"2466214222","title":"Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Spruce Biosciences (SPRB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466214222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466214222?lang=en_us&edition=fundamental","pubTime":"2024-09-12 12:30","pubTimestamp":1726115442,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acrivon Therapeutics, Inc. (ACRV – Research Report) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acrivon-therapeutics-inc-acrv-and-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acrivon-therapeutics-inc-acrv-and-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCSG","BK4137","ACRV","SPRB"],"gpt_icon":0},{"id":"2464358868","title":"Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2464358868","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464358868?lang=en_us&edition=fundamental","pubTime":"2024-09-04 04:01","pubTimestamp":1725393660,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., September 03, 2024----Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 p.m. ET.Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF1 receptor antagonist, for the treatment of congenital adrenal hyperplas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.4qbg4AXoTXbBDFGbMnA8Q--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f28cd107c0367e6e8a4ff69355170b00","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.4qbg4AXoTXbBDFGbMnA8Q--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f28cd107c0367e6e8a4ff69355170b00"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-participate-h-c-200100401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0310799852.SGD","CAH","LU0310800965.SGD","LU0211328371.USD","LU0211327993.USD","LU0052756011.USD","BK4588","LU0792757196.USD","BK4175","LU0006061336.USD","LU1571399168.USD","LU1880398471.USD","LU1267930490.SGD","SPRB","BK4139","LU0889566641.SGD","LU1267930813.SGD","BK4585","LU0128525689.USD","LU1880398554.USD","SG9999001440.SGD","LU1267930227.SGD"],"gpt_icon":0},{"id":"2460404930","title":"Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2460404930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460404930?lang=en_us&edition=fundamental","pubTime":"2024-08-20 15:02","pubTimestamp":1724137334,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pyxis Oncology (PYXS – Research Report), Spruce Biosciences (SPRB...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-spruce-biosciences-sprb-and-envista-holdings-nvst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-spruce-biosciences-sprb-and-envista-holdings-nvst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4082","NVST","PYXS","SPRB","BK4139","BK4137"],"gpt_icon":0},{"id":"2460908123","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2460908123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460908123?lang=en_us&edition=fundamental","pubTime":"2024-08-19 18:30","pubTimestamp":1724063427,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kronos Bio (KRON – Research Report), Spruce Biosciences (SPRB – R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kronos-bio-kron-spruce-biosciences-sprb-and-scpharmaceuticals-scph?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kronos-bio-kron-spruce-biosciences-sprb-and-scpharmaceuticals-scph?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4505","BK4007","BK4137","SCPH","KRON","SPRB","BK4139"],"gpt_icon":0},{"id":"2459817291","title":"Spruce Biosciences Price Target Maintained With a $2.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2459817291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459817291?lang=en_us&edition=fundamental","pubTime":"2024-08-14 00:39","pubTimestamp":1723567140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 13, 2024 12:39 ET (16:39 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB"],"gpt_icon":0},{"id":"2459002069","title":"Spruce Biosciences GAAP EPS of -$0.22 beats by $0.01, revenue of $1.61M beats by $0.69M","url":"https://stock-news.laohu8.com/highlight/detail?id=2459002069","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459002069?lang=en_us&edition=fundamental","pubTime":"2024-08-13 22:45","pubTimestamp":1723560329,"startTime":"0","endTime":"0","summary":"Spruce Biosciences press release  (NASDAQ:SPRB): Q2  GAAP EPS of -$0.22  beats by $0.01.\nRevenue of $1.61M (-25.8% Y/Y)  beats by $0.69M.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4139237-spruce-biosciences-gaap-eps-of-0_22-beats-0_01-revenue-of-1_61m-beats-0_69m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SPRB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0605},{"period":"1month","weight":0.1046},{"period":"3month","weight":0.1621},{"period":"6month","weight":-0.3184},{"period":"1year","weight":-0.5085},{"period":"ytd","weight":-0.8255}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.022},{"period":"3month","weight":0.0798},{"period":"6month","weight":0.1279},{"period":"1year","weight":0.3308},{"period":"ytd","weight":0.2564}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.33989},{"month":2,"riseRate":0.5,"avgChangeRate":0.009378},{"month":3,"riseRate":0,"avgChangeRate":-0.297383},{"month":4,"riseRate":0,"avgChangeRate":-0.078867},{"month":5,"riseRate":0.5,"avgChangeRate":-0.003763},{"month":6,"riseRate":0.25,"avgChangeRate":-0.126985},{"month":7,"riseRate":0.5,"avgChangeRate":-0.017508},{"month":8,"riseRate":0.25,"avgChangeRate":-0.021147},{"month":9,"riseRate":0.5,"avgChangeRate":-0.141116},{"month":10,"riseRate":0.25,"avgChangeRate":-0.193698},{"month":11,"riseRate":0.4,"avgChangeRate":0.006449},{"month":12,"riseRate":0.5,"avgChangeRate":0.416923}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction